ADVANCED COURSE PROGRAMME

Prostate Cancer

ESMO VIRTUAL ADVANCED COURSE

ONLINE
30-31 MARCH 2022

Chairs:
Elena Castro, Spain
Fabio Schütz, Brazil
ESMO VIRTUAL ADVANCED COURSE PROGRAMME
CLINICAL QUESTIONS IN PROSTATE CANCER

30-31 March 2022

CO-CHAIRS: Elena Castro, Spain
Fabio Schütz, Brazil

SPEAKERS: Maria Teesa Bourlon, Mexico
Stefano Fanti, Italy
Valérie Fonteyne, Belgium
Pernelle Lavaud, France
Murilo Luz, Brazil
Ray Manneh, Colombia
Juan Pablo Sade, Argentina
Rafael Sanchez Salas, Canada

LEARNING OBJECTIVES

- To understand essentials in the assessment and the value of multidisciplinary management of prostate cancer
- To learn about state-of-the-art advances in treatment of prostate cancer
- To learn the principles of management of advanced prostate cancer through direct exposure to real clinical scenarios

ACCREDITATION

The programme of this virtual event has been accredited with 6 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

astellas

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
**All timings are to be considered CEST (Central European Summer Time)**

**Wednesday, 30 March 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30–15:35</td>
<td><strong>Welcome and course overview</strong>&lt;br&gt;5’&lt;br&gt;Elena Castro, ES&lt;br&gt;Fabio Schütz, BR</td>
</tr>
<tr>
<td>15:35–16:15</td>
<td><strong>Session 1</strong>&lt;br&gt;State-of-the-art in prostate cancer diagnostics&lt;br&gt;15’&lt;br&gt;PSMA based diagnostics: The future of imaging&lt;br&gt;Stefano Fanti, IT&lt;br&gt;15’&lt;br&gt;Biology: Clinical genomics in prostate cancer management&lt;br&gt;Elena Castro, ES&lt;br&gt;10’&lt;br&gt;Discussion&lt;br&gt;Faculty</td>
</tr>
<tr>
<td>16:15–16:55</td>
<td><strong>Session 2</strong>&lt;br&gt;High risk localized prostate cancer&lt;br&gt;15’&lt;br&gt;Role of radiotherapy: Recent advances in RT modalities <em>(including hypofractionation, brachytherapy, SABR)</em>&lt;br&gt;Valérie Fonteyne, BE&lt;br&gt;15’&lt;br&gt;High risk localized disease: Integrating drugs with local treatments&lt;br&gt;Murilo Luz, BR&lt;br&gt;10’&lt;br&gt;Discussion&lt;br&gt;Faculty</td>
</tr>
<tr>
<td>16:55–17:10</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>17:10–18:05</td>
<td><strong>Session 3</strong>&lt;br&gt;Intermediate situation of advanced prostate cancer&lt;br&gt;15’&lt;br&gt;Rising PSA: biochemical recurrence management&lt;br&gt;Rafael Sanchez Salas, CA&lt;br&gt;15’&lt;br&gt;Oligometastatic prostate cancer&lt;br&gt;Valérie Fonteyne, BE&lt;br&gt;15’&lt;br&gt;M0 Castrate Resistant Prostate Cancer (CRPC): What are our latest options?&lt;br&gt;Juan Pablo Sade, AR&lt;br&gt;10’&lt;br&gt;Discussion&lt;br&gt;Faculty</td>
</tr>
</tbody>
</table>
Session 4
Metastatic prostate cancer - Part 1

15'
Metastatic hormone sensitive prostate cancer: State of the art management in 2022
Fabio Schütz, BR

15'
Metastatic CRPC: Standard of care in 2022 (including bone targeting agents)
Ray Manneh, CO

10'
Discussion
Faculty

Thursday, 31 March 2022

Session 5
Metastatic prostate cancer - Part 2

15'
Metastatic CRPC: What's on the horizon — new treatments (targeted therapies, PARP inhibitors)
Maria Teresa Bourlon, MX

15'
Metastatic CRPC: What's on the horizon — new treatments (immunotherapy, BiTE and others)
Pernelle Lavaud, FR

10'
Discussion
Faculty

Workshops sessions
Three workshops sessions
10' Introduction based on clinical cases presented by speakers
30' Discussion

Workshop 1
Localized prostate cancer
60'
Valérie Fonteyne, BE
Rafael Sanchez Salas, CA

17:10–17:25
Break

Workshop 2
High risk/locally advanced prostate cancer
60'
Murilo Luz, BR
Juan Pablo Sade, AR

Workshop 3
Metastatic prostate cancer
30'
Pernelle Lavaud, FR

18:55–19:00
Conclusion and farewell
Elena Castro, ES
Fabio Schütz, BR